Phosphate control in peritoneal dialysis

Mario Cozzolino, Andrea Stucchi, Maria Antonietta Rizzo, Irene Brenna, Francesca Elli, Paola Ciceri, Jordi Bover, Daniele Cusi, Maurizio Gallieni

Research output: Chapter in Book/Report/Conference proceedingChapter


Chronic kidney disease (CKD) is characterized by phosphorus retention and, in more advanced stages, by high serum phosphorus (P) levels. During the last decade, it has been elucidated the central role of P in the pathogenesis of CKD mineral bone disorder (CKD- MBD), determining both renal osteodystrophy and cardiovascular disease. Unfortunately, at least one third of patients on chronic dialysis have high serum P levels, with a consequent higher serum PTH levels, commonly associated with vitamin D deficiency, increased vascular calcification and the highest ratios of morbidity and mortality. In patients with CKD stage 5 on dialysis, therapeutic approaches to reduce serum P levels should include restriction of dietary phosphate intake, optimal dialysis treatment, and use of P binders. In this context, the use of P binders appears to be an essential treatment to control P overload in CKD patients. In this review, we analyzed the use of calcium- based and calcium- free P binders in peritoneal dialysis patients.

Original languageEnglish
Title of host publicationPeritoneal Dialysis - State-of-the-Art 2012
PublisherS. Karger AG
Number of pages8
ISBN (Print)9783318021639, 9783318021622
Publication statusPublished - May 30 2012

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Phosphate control in peritoneal dialysis'. Together they form a unique fingerprint.

Cite this